Successful treatment of osimertinib-resistant EGFR-mutant NSCLC with acquired BRAF V600E mutation using triple combination therapy: a case report with pathological confirmation.

doi:10.1186/s12957-025-04011-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Successful treatment of osimertinib-resistant EGFR-mutant NSCLC with acquired BRAF V600E mutation using triple combination therapy: a case report with pathological confirmation.

World journal of surgical oncology - 10 Oct 2025

Lin MingHui, Chen XuYu, Lin Fan, Yang YanBo

Abstract excerpt

BACKGROUND: Non-small cell lung cancer (NSCLC) with EGFR mutations often develops resistance to tyrosine kinase inhibitors (TKIs), with acquired BRAF V600E mutation being a rare but clinically challenging mechanism. The efficacy of combined EGFR and BRAF/MEK inhibition in this setting is not sufficiently characterized. CASE PRESENTATION: A 56-year-old never-smoker with stage IVA EGFR exon 19del-mutant lung...

Read the complete abstract on PubMed

Topics

Humans
Aniline Compounds
Acrylamides
Middle Aged
Proto-Oncogene Proteins B-raf
Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Carcinoma, Non-Small-Cell Lung

ErbB Receptors

Drug Resistance, Neoplasm

Female

Antineoplastic Combined Chemotherapy Protocols

Mutation

Oximes

Pyrimidinones

Pyridones

Imidazoles

Protein Kinase Inhibitors

Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41074181
DOI: 10.1186/s12957-025-04011-w
PMCID: PMC12512737

Genes

EGFR
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of osimertinib-resistant EGFR-mutant NSCLC with acquired BRAF V600E mutation using triple combination therapy: a case report with pathological confirmation.PMID 41074181Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.Semantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.Semantic proximity Read ↗

New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era.Semantic proximity Read ↗

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.Semantic proximity Read ↗

Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.Semantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment.Semantic proximity Read ↗

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.